We definitely have current biomarkers limitations in the diagnosis of AD and other major neurodegenerative diseases (50, 51) and their overlap cannot be ignored because the prevalence of AD with α-synuclein and TDP-43 will most certainly complicate efforts to identify therapies to treat lethal diseases as clearly stated by Karanth et al. (28). This evidence concerns the gene TARDBP and Alzheimer disease.